NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
One of the main challenges identified by the research was that, although the European Medicines Agency (EMA) approves new ...
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
A new survey has revealed the huge scale and mindboggling complexity of the task facing pharma in keeping medicines moving around Europe after Brexit. No-one knows if or when the EU27 and the UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results